Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in
adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe
keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or
matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up
to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period,
followed by a 2-week follow-up period.